Esther H Steinhauer

Learn More
Patients with advanced cancer exhibited lower natural cytotoxicity against K562 target cells in a standard short-term chromium release assay than did patients with localized malignancy or normal individuals. Although natural killer (NK) activity of advanced cancer patients could be augmented by nylon column depletion of adherent cells and enriched further(More)
Natural cytotoxicity was measured in 51 adult patients with solid epithelial malignant tumors and in 27 normal subjects. Peripheral blood leukocytes (PBL) from 31% of the patients and 7% of the controls failed to kill target cells (K562) in a short-term chromium-release assay. When patients were classified according to clinical stage, PBL from 12% of(More)
We have taken the approach of producing somatic cell variants with altered H-2 products to study the structural requirements for cell surface expression of class I histocompatibility molecules. H-2 antigen variants generated by chemical mutagenesis of a cell line expressing the H-2b haplotype were first selected with alloantisera for their loss of H-2Kb(More)
Advanced cancer patients were studied for their ability to produce natural killer cytotoxic factor (NKCF). Of 23 patients with advanced epithelial cancers, 8 showed deficient natural killer (NK) activity, as measured in a standard 51Cr release assay. Lymphocytes from these patients did not generate NKCF (nonproducers) in the presence of K562 cells. In(More)
The relationship between production of NKCF and IFN-alpha by human lymphocytes was studied. NKCF activity was generated in response to K562-inducer cells. The presence of NKCF in supernatants was always accompanied by antiviral activity, but in several experiments IFN was detected without concomitant NKCF. In no instance was NKCF activity detected in the(More)
  • 1